InvestorsHub Logo
Followers 253
Posts 18004
Boards Moderated 0
Alias Born 01/19/2006

Re: None

Wednesday, 09/29/2021 4:50:21 PM

Wednesday, September 29, 2021 4:50:21 PM

Post# of 58
From Dew Diligence, 9/28/2021:

FDA approves ABBV’s Qulipta—(atogepant)—for migraine prevention:

https://finance.yahoo.com/news/fda-approves-qulipta-atogepant-first-224200797.html

Qulipta will compete with BHVN’s Nurtec ODT, which is approved for both prevention and acute treatment (#msg-164076435, #msg-154072129).

ABBV now has three approved agents in its migraine portfolio: Qulipta; Ubrelvy (approved for acute treatment in 2019 [#msg-154072129]); and Botox. All three came to ABBV by way of Allergan.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BHVN News